Atara Biotherapeutics, Inc. — Director's Dealing 2019

Mar 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atara Biotherapeutics, Inc. (ATRA)
CIK: 0001604464
Period of Report: 2019-03-26

Reporting Person: Porter Derrell (SVP, Head of Global Commercial)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-26	Common Stock	A	10000	$0.00	Acquired	31688	Direct

Footnotes

F1: These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting
person's continuous service.